Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia and its ...

The European health regulator said on Friday it has started a review of anti hair-loss drugs, including Merck's Propecia, ...

Vice President Kamala Harris allies in the business community are trying to give her a boost over Donald Trump.

We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...

Anyone crafting a bull case for the pharmaceutical giant Merck (NYSE: MRK) should include Keytruda as the company's best ...

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia, for the ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, ...

Societe Generale has recently reduced Merck & Co Inc (MRK) stock to Sell rating, as announced on March 11, 2024, according to Finviz. Earlier, on January 4, 2024, TD Cowen had raised the stock from a ...

Merck (MRK) is one of the worst-performing stocks in the Dow Jones Industrial Average (DJIA) on Thursday. The US government ...